NASDAQ:CUE
Cue Biopharma Stock Nearly Doubles After Allergy Drug Deal, New CEO and $30 Million Raise
Cue Biopharma surged Friday morning, the stock boosted by news of a fresh allergy drug license. The Boston biotech also unveiled a $30 million private placement and named Shao-Lee Lin as its new chief…
Company hubNASDAQ:CUE
Cue Biopharma (CUE) Stock News & Analysis
Follow the latest Cue Biopharma (CUE) company news, earnings coverage and investor analysis from TechStock².
Save this hub to your TS2 Signalbook account.
- Latest update
- Articles in this hub
- 1
- Last 30 days
- 0
What investors are watching
- Earnings, guidance and financial performance
- Valuation, trading activity and market sentiment
- Strategy, catalysts and company-specific risks
All coverage